FY2024 EPS Estimates for Theratechnologies Inc. (NASDAQ:THTX) Raised by Analyst

Theratechnologies Inc. (NASDAQ:THTX) – Stock analysts at Cantor Fitzgerald increased their FY2024 earnings per share estimates for Theratechnologies in a research note issued to investors on Thursday, April 11th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of $0.00 for the year, up from their previous forecast of ($0.06). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Theratechnologies’ current full-year earnings is ($0.03) per share.

Theratechnologies Stock Down 1.5 %

THTX stock opened at $1.28 on Monday. Theratechnologies has a 52-week low of $0.88 and a 52-week high of $4.30. The stock has a market capitalization of $30.98 million, a price-to-earnings ratio of -2.10 and a beta of 1.34. The stock’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $1.55.

Theratechnologies (NASDAQ:THTX) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.16. The business had revenue of $23.45 million for the quarter. During the same quarter last year, the business earned ($0.36) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Atria Wealth Solutions Inc. bought a new stake in Theratechnologies in the second quarter valued at about $33,000. Kohmann Bosshard Financial Services LLC bought a new stake in Theratechnologies in the third quarter valued at about $33,000. HighTower Advisors LLC bought a new stake in Theratechnologies in the first quarter valued at about $34,000. Range Financial Group LLC bought a new stake in Theratechnologies in the first quarter valued at about $35,000. Finally, Virtu Financial LLC bought a new stake in Theratechnologies in the first quarter valued at about $36,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.